



FOR IMMEDIATE RELEASE

CONTACT: Molly Watson, M: (413) 454-3926, molly.watson@ritzcommunications.com

Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease

MSDC to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

KALAMAZOO, Mich., March 18, 2015 – Metabolic Solutions Development Company (MSDC), an emerging biopharmaceutical company developing first in class therapeutics to treat diseases associated with metabolic dysfunction, today announced that Stephen Benoit, CEO, will present a company overview at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015, at 2:30 p.m. ET at the Millennium Broadway Hotel in New York City.

Mr. Benoit's presentation will include an overview of the company's development plans for its lead compound, MSDC-0602, which is expected to enter into large Phase 2b clinical trials in 2015 in patients diagnosed with nonalcoholic steatohepatitis known as NASH and polycystic kidney disease (PKD), respectively.

Presentation and Breakout Room/Time

Presentation: Room 302/303 from 2:30-2:55pm ET

Breakout: Room 301 from 3:00-3:30pm ET

A live webcast of the presentation can be accessed under "Presentations" in the Newsroom section of the Company's website at www.msdrx.com. An archived webcast recording will be available on the MSDC website for approximately 60 days.

About Metabolic Solutions Development Company

Metabolic Solutions Development Company (www.msdrx.com) is an emerging biopharmaceutical company developing first in class oral therapeutics to treat diseases associated with metabolic dysfunction, including NASH, polycystic kidney disease, and diabetes, as well as neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

###